[Treatment of wet age-related macular degeneration with vascular endothelial growth factor. A survey of a Cochrane review]

Ugeskr Laeger. 2009 Nov 16;171(47):3435-7.
[Article in Danish]


This evaluation of a Cochrane-review including five clinical trials of good methodological quality indicates that the antiangiogenic therapeutic agents, pegaptanib and ranibizumab, are effective treatment strategies for neovascular Age-Related Macular Degeneration (AMD). The review does not include a direct comparison or an indirect statistical comparison between the two antiangiogenic agents. In clinical practice ranibizumab compared to pegaptanib is the drug of choice because of cost-utility analysis and the number of patients gaining visual acuity.

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Aged
  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Aptamers, Nucleotide / therapeutic use
  • Evidence-Based Medicine
  • Humans
  • Porphyrins / therapeutic use
  • Ranibizumab
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A / therapeutic use*
  • Wet Macular Degeneration / drug therapy*


  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Aptamers, Nucleotide
  • Porphyrins
  • Vascular Endothelial Growth Factor A
  • pegaptanib
  • Ranibizumab